NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
Clinical Trials
11 trialsNCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00129935 2023-03-31
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00087178 2022-08-11
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01966471 2022-06-14
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03556358 2022-01-14
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With HerceptinĀ® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc.
Phase 3 Completed
NCT00014222 2020-10-05
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00513292 2019-01-23
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00066807 2016-10-28
PERCHE
ETOP IBCSG Partners Foundation
Phase 3 Terminated